This is a study to observe the effects of CagriSema on heart disease in people living with obesity, and diseases of the heart and blood vessels.
Staus:
Closed
Clinical Description:
This study will evaluate the effects of CagriSema on cardiovascular events in people living with obesity and cardiovascular disease. The participants with either get CagriSema or Placebo.
Target Age/Sex:
Male & Female, age 55 years or above BMI of >30 with established cardiac disease
Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures.